Sodium-glucose cotransporter 2 inhibitors (SGLT-2 inhibitors) such as Invokana, Jardiance, and Farxiga have a higher risk of leg, feet, and toe amputations drug-class side effect when compared to older diabetes drugs such as sulfonylureas, metformin, and thiazolidinediones. This finding was reported in the article “Association Between … [Read more...]
New SGLT2 Inhibitor Diabetes Drugs to Hit the Market in January
Approval On December 19, 2017, the FDA approved Merck & Co. and Pfizer's new diabetes drug, Steglatro, and its two combination versions, Steglujan and Segluromet. These drugs are classified as sodium/glucose cotransporter 2 (SGLT2) inhibitors, and will be available this coming January. Steglatro consists of ertugliflozin, while Steglujan … [Read more...]
Jardiance – Lower Limb Amputations Drug Safety Issue Remains Uncertain
It appears there needs to more medical research done on the risk of lower limb amputations for patients who use the increasing popular diabetes medicines in the sodium glucose cotransporter 2 (SGLT2) inhibitor class, such as canagliflozin (Invokana / Invokamet), empagliflozin (Jardiance / Glyxambi / Synjardy), and dapagliflozin (Farxiga / Xigduo / … [Read more...]
New Analysis Finds An Increased Risk Of Bladder Cancer For Jardiance
This article, “SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials”, was published in the October 2017 edition of Diabetologia. It presents the findings of medical researchers who conducted a systematic literature review to identify randomized controlled trials that reported … [Read more...]
SGLT2 Inhibitors May Have an Increased Risk of Acute Renal Failure
SGLT2 Inhibitors: A New Side Effect In previous articles, I have discussed SGLT2 inhibitor diabetes drugs such as Invokana, Farxiga, and Jardiance and the adverse events associated with them. Such side effects include diabetic ketoacidosis (DKA) and lower-limb amputations. A recent study identified a new possible side effect of these drugs … [Read more...]
Could Invokana have been the cause of my lower-limb amputation?
The FDA is investigating a connection between diabetes drugs belonging to the Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitors class of drugs and the following side effects: Diabetic Ketoacidosis (DKA) Ketoacidosis Ketosis Acute Kidney Injury Kidney Failure / Renal Failure Kidney Damage Pyelonephritis (kidney infection) … [Read more...]
Can SGLT-2 Inhibitor Diabetes Drugs Increase Your Risk of Stroke?
While we have frequently discussed DKA, kidney damage, and amputations as possible side effects of diabetes drugs in the SGLT-2 inhibitors class -- such as Farxiga, Invokana, Jardiance -- strokes and thromboembolic events are also considered potential harmful effects of these drugs. Based on FAERS reports received during the second quarter of … [Read more...]
Jardiance, Invokana, And Farxiga Double Risk Of Diabetic Ketoacidosis
The June 8, 2017 edition of The New England Journal of Medicine (NEJM) has a “To the Editor” letter, titled “Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor”, which is likely causing some concerns among doctors and type 2 diabetes (T2D) patients. It is about the safety of Jardiance, Invokana, Farxiga, and other diabetes … [Read more...]
Farxiga MDL Includes Diabetic Ketoacidosis And Kidney Damage Lawsuits
On April 6, 2017 the United States Judicial Panel On Multidistrict Litigation (JPML) issued this document, “IN RE: FARXIGA (DAPAGLIFLOZIN) PRODUCTS LIABILITY LITIGATION TRANSFER ORDER — MDL No. 2776”, from which we get the following information: On the basis of the papers filed and the hearing session held, we find that these actions involve … [Read more...]
Farxiga / Jardiance / Invokana: Label Change Adds Ketoacidosis Warning
In August 2016 the FDA sent letters to Janssen Pharmaceuticals and AstraZeneca Pharmaceuticals for label changes about fatal cases of ketoacidosis cases involving Invokana (canagliflozin), Invokamet (canagliflozin and metformin), Farxiga (dapagliflozin), and Xigduo XR (dapagliflozin and metformin extended-release). As for the other diabetes … [Read more...]